(1)Tacha et al., Distinguishing Adenocarcinoma from Squamous Cell Carcinoma in the Lung Using Double Stains, Mod Pathol 2010; 23 Suppl 1:415A- 416A.
About Biocare Medical
Biocare Medical, LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC tests which provide increased confidence at critical diagnostic decision points, impacting patient therapy while accelerating turnaround time. Biocare’s advanced micro-polymer™ detection enables unsurpassed specificity and sensitivity. PROMARK™ and “mouse on mouse” IHC detection kits are optimized for rat and mouse tissues and feature proprietary blocking and retrieval reagents, resulting in virtually background free IHC staining.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets with novel tissue immunohistochemistry and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Biocare announced the favorable resolution of a challenge to its non-exclusive worldwide license for p63 antibodies in 2008. The United States District Court's ruling in favor of Biocare reinforced and confirmed its right to "make, use or sell" IVD p63 antibodies, which makes use of discoveries made at Harvard University and covered under United States patent nos. 6,946,256 and 7,030,227. A subsequent appeal of that ruling was unsuccessful and did not alter Biocare's license agreement with Harvard. Moreover, customers should ignore any press releases by competitors that announce an "exclusive" license or distributorship agreement for p63 as they are untrue.
p63 is also featured in several of Biocare’s novel multiplex IHC products. PIN-4™, ADH-5™, Lung Adeno-2™ and Lung Sqamous-2™ help to differentiate: five phenotypes of breast cancer; PIN vs. prostate cancer vs. benign disease; and lung adeno- vs. squamous cell carcinoma.
Laboratories may contact their local Biocare Medical Sales Representative or distributor for more information or visit http://www.biocare.net/p63
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC tests which provide increased confidence at critical diagnostic decision points, impacting patient therapy while accelerating turnaround time. Biocare’s advanced micro-polymer™ detection enables unsurpassed specificity and sensitivity. PROMARK™ and “mouse on mouse” IHC detection kits are optimized for rat and mouse tissues and feature proprietary blocking and retrieval reagents, resulting in virtually background free IHC staining.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets with novel tissue immunohistochemistry and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
The result is clear: virtually no background, a clean chromogenic signal. You can visualize the target under brightfield microscopy, along with the tissue morphology on a single slide. This 5-step procedure is as simple as IHC – bringing what was once considered a tedious technology to every lab.
We will be launching with a small subset of probes initially, these RISH™ Probes are designed for the diagnosis and classification of hematopoietic and lymphoid neoplasms: EBER, Kappa and Lambda Light Chains.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Please contact your local Biocare Medical Sales Representative for more information or visit http://www.biocare.net/rish.html
Biocare Medical’s Decloaking Chambers are the most validated and well-published tools for heat induced epitope-retrieval (HIER) methods. All Decloaker HIER solutions incorporate Assure™ color-coded pH indicator technology, indicating by visual inspection that the solution is at the correct dilution and pH.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Since debuting in 1991, the Inc. magazine list of the most rapidly growing private companies has served evidence of the significant accomplishments of entrepreneurial companies. As an Inc. 5000 honoree, Biocare Medical shares a prestigious pedigree with some of the most successful businesses in America.
“Savvy trend spotters and those who invest in private companies know that the Inc. 5000 is the best place to find out about young companies that are achieving success through a wide variety of unprecedented business models, as well as older private companies that are still expanding at an impressive rate,” said Inc. 5000 project manager Jim Melloan. “That’s why our list is so eagerly anticipated every year.”
Since its launch in 1997, Biocare Medical has made a significant leap towards achieving its goal of becoming the most trusted source for cancer diagnostics with strong commitment to patient care and the highest quality IHC and molecular pathology products.
The Inc. 5000 is ranked according to each company's percentage of revenue growth from 2005 through 2008. To qualify, companies must be U.S.-based, privately held, for profit, and independent -- not subsidiaries or divisions of other companies.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
About Inc.com:
Inc.com, the Daily Resource for Entrepreneurs, delivers advice, tools, breaking news, and rich multimedia to help business owners and CEOs start, run, and grow their businesses more successfully. Information and advice covering virtually every business and management task, including marketing, sales, finding capital, managing people can be found at www.inc.com.
Biocare is dedicated to improving patient care and providing the best IHC and molecular pathology products for early and accurate diagnosis and prognosis of cancers and to support therapeutic decisions. We realize that each product we make and each result generated can impact a patient’s life. There are many people behind each test result: a patient anxiously awaiting the results of a diagnostic, prognostic or predictive test; a laboratorian depending on the accuracy of our chemistries and consistency of our instruments and software, to work every time; and a pathologist needing precise, clean and brilliant staining to solve difficult clinical problems.
Biocare Medical would like to thank the readers of ADVANCE for Administrators of the Laboratory for voting us your ‘Top of the Class’ company in both the Histology and Pathology categories. Your support has enabled Biocare Medical to earn the last three consecutive Histology awards.
This year’s award for Pathology further encourages us to continue to strive for superior quality IHC and molecular pathology products. We have focused our efforts on both instrumentation and creating world class chemistries that will yield the highest quality IHC staining results. Your support has enabled us to become the industry leader in developing novel simultaneous multiplex staining, thereby providing easier interpretation and shorter turn around time to pathologists. At Biocare Medical, our goal is to provide the highest quality products and excellent customer service to ensure that our products perform exactly as described.
Biocare is currently moving into molecular pathology with our HER2 CISH Kit to detect HER2 gene amplification. We will continue to deliver innovative and cutting edge products that will contribute to the global effort to fight cancer. We sincerely thank you for your continued recognition and dedicated support.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
Biocare Medical LLC was distinguished as “Top of the Class” for histology in 2005, 2006 and 2008, and for pathology in 2008, based on lab survey results in Advance for Administrators of the Laboratory magazine. The criteria cited included “Great customer service”, “High-quality IHC antibodies and reagents”, and “Products perform exactly as described at an unmatched price and quality”. These awards recognize our commitment to patient care and the highest quality IHC and molecular pathology products.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
For more information on this and other multiplex IHC products contact Biocare Medical Customer Service at 1-800-799-9499 or visit us at www.biocare.net
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
Biocare Medical LLC was distinguished as “Top of the Class” for histology in 2005, 2006 and 2008, and for pathology in 2008, based on lab survey results in Advance for Administrators of the Laboratory magazine. The criteria cited included “Great customer service”, “High-quality IHC antibodies and reagents”, and “Products perform exactly as described at an unmatched price and quality”. These awards recognize our commitment to patient care and the highest quality IHC and molecular pathology products.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Specifically designed with the clinical diagnostic laboratory in mind, the intelliPATH FLX offers true continuous random access using Multi-Batch Processing (MBP) technology to process 5 runs simultaneously. The Flexibility of a fully open system; use any antibody, detection system or chromogen to run multiple protocols in the same batch; select from Biocare’s validated protocols or create your own. Prioritized STAT Processing delivers results when you need them. Scheduling software prioritizes STAT cases, delivering rapid results in as little as 60 minutes.
The intelliPATH FLX features convenient walk-away automation with on-line preparation of chromogens and enzymes. Featuring scheduling software for faster slide processing and time to result. Unique simultaneous X, Y and Z (azimuthal) movement and the multi-dispensing reagent syringe decreases reagent dispensing time up to 20%. Positive slide and reagent ID, eliminates manual data entry, reducing sample ID errors.
Control up to 4 intelliPATH FLX instruments from one computer; share-data, such as protocols, reagent inventory, test and patient information. The intelliPATH FLX has uni- or bi-directional LIS interfaces; compatible with XML, HL-7 and other communication standards. Inventory management tracks the reagent lot number, expiration dates and remaining reagent volume.
The intelliPATH FLX is the only complete system for simultaneous multiplex stains, reducing lab and pathologist workload. Optimized for rapid 4-step multiplex stains the intelliPATH FLX offers greater flexibility. Perform multiplex stains in virtually the same turn around time as a single stain. Reduce total slide volume/workload resulting in reduced reagent and labor costs.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
Biocare Medical LLC was distinguished as “Top of the Class” for histology in 2005, 2006 and 2008, and for pathology in 2008, based on lab survey results in Advance for Administrators of the Laboratory magazine. The criteria cited included “Great customer service”, “High-quality IHC antibodies and reagents”, and “Products perform exactly as described at an unmatched price and quality”. These awards recognize our commitment to patient care and the highest quality IHC and molecular pathology products.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Biocare Medical , LLC of Concord, California is pleased to announce favorable resolution of a challenge to its non-exclusive worldwide license for p63 antibodies. The judgment makes Biocare one of only two companies that have rights to “make, use or sell” p63 antibodies, which make use of discoveries made at Harvard College.
Following litigation launched in 2007 by AsymmetRx, a Connecticut based company, alleging infringement of p63-related patents licensed by AsymmetRx, Biocare’s previous license to p63 was supported by the court. A Summary Judgment was granted on September 29, 2008 by order to the United States District Court for the District of Massachusetts that supports Biocare’s license to “make, use or sell”. On June 27, 2007, AsymmetRx commenced litigation challenging Biocare’s intellectual property license for p63. The patents under dispute were United State patent no. 6,946,256 entitled “Cell Regulatory Genes, encoded Products and Uses Related Thereto” and United States patent 7,030,227 entitled “Cell Regulatory Genes, encoded Products and Uses Related Thereto”.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time.
Biocare Medical LLC was distinguished as “Top of the Class” for histology in 2005, 2006 and 2008, and for pathology in 2008, based on lab survey results in Advance for Administrators of the Laboratory magazine. The criteria cited included “Great customer service”, “High-quality IHC antibodies and reagents”, and “Products perform exactly as described at an unmatched price and quality”. These awards recognize our commitment to patient care and the highest quality IHC and molecular pathology products.
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Approximately one million people worldwide are screened each year for HER2 amplification or over-expression. The importance of genetic tests like HER2 CISH is growing because some targeted cancer therapies (like trastuzumab) are most effective in patients who overexpress the HER2 gene. The primary users will be pathologists, oncologists, and histotechnologists who will determine the best course of treatment for breast cancer patients. The SPOT-Light® test uses standard histology laboratory methods and equipment to yield valuable gene status information.
“We are pleased to bring this kit to market so quickly after receiving FDA approval,” said Brett Williams, head of Invitrogen’s Anatomical Pathology Business. “Working with the Biocare sales force, we believe we will be able to more rapidly and efficiently deliver this critical diagnostic product to clinicians who are making life-saving decisions for their breast cancer patients.
“Biocare’s rapid growth has been fueled by providing award winning technical and customer service in addition to novel products for anatomic pathology and research laboratories,” said Roy Yih, Biocare Chief Executive Officer. “We are enthusiastic about being selected as the exclusive U.S. distribution channel for the SPOT-Light HER2 CISH Kit. This product is the first FDA approved product to provide the confidence and objectivity of in-situ hybridization with the ease of immunohistochemistry, enabling a wider number of anatomic pathology laboratories to perform this critical test.”
Per FDA requirements, laboratories must be certified prior to purchasing the SPOT-Light® HER2 CISH Kit for use on patient specimens. One user per laboratory must successfully complete Invitrogen’s HER2 CISH certification program. Full certification details are available at www.invitrogen.com/her2cishcert. After certification, the SPOT-Light® HER2 CISH Kit may be ordered by calling (800) 799-9499 or at www.biocare.net/order.
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.
About Biocare Medical
Biocare Medical LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous multiplex stain IHC and antibody cocktail development which solves difficult clinical problems and accelerates turnaround time
The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to; a) Invitrogen and Biocare will be able to offer the product rapidly and efficiently to clinicians. Potential risks and uncertainties include, but are not limited to; 1) the SPOT-Light HER2 CISH Kit may or may not be the first FDA approved product to provide the confidence and objectivity of in-situ hybridization with the ease of immunohistochemistry; 2) the SPOT-Light HER2 CISH Kit may or may not enable a wider number of anatomic pathology laboratories to perform this critical test; as well as the risks that the market will not accept the companies’ products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
Herceptin® is a registered trademark of Genentech. No sponsorship or endorsement by Genentech is implied herein.
Media Contact:
Invitrogen Corporation, Revelle Bailey, (760) 268-7482, revelle.bailey@invitrogen.com
